USANA Health Sciences (NYSE:USNA) Upgraded at DA Davidson

DA Davidson upgraded shares of USANA Health Sciences (NYSE:USNA) to a hold rating in a report issued on Friday morning,Zacks.com reports.

Separately, StockNews.com raised USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday.

USANA Health Sciences Price Performance

NYSE:USNA opened at $33.38 on Friday. The firm has a market capitalization of $636.22 million, a PE ratio of 11.80, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. The business’s fifty day moving average price is $37.91 and its 200 day moving average price is $40.25. USANA Health Sciences has a 12 month low of $33.28 and a 12 month high of $54.81.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same quarter in the previous year, the firm earned $0.59 earnings per share. As a group, equities analysts anticipate that USANA Health Sciences will post 2.45 EPS for the current year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 675 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $37.71, for a total value of $25,454.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

A number of institutional investors have recently added to or reduced their stakes in USNA. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences in the third quarter valued at about $30,000. KBC Group NV raised its holdings in shares of USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the period. BOKF NA lifted its position in USANA Health Sciences by 99.4% during the 2nd quarter. BOKF NA now owns 5,526 shares of the company’s stock worth $250,000 after acquiring an additional 2,755 shares in the last quarter. Centiva Capital LP purchased a new position in USANA Health Sciences in the 3rd quarter worth approximately $213,000. Finally, Quest Partners LLC acquired a new stake in USANA Health Sciences in the third quarter valued at approximately $250,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.